{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T08:21:03Z","timestamp":1775809263141,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Peking University Clinical Research Program","award":["PUCRP201305"],"award-info":[{"award-number":["PUCRP201305"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s10067-020-05043-1","type":"journal-article","created":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T15:02:45Z","timestamp":1584975765000},"page":"2573-2581","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The predictive value of serum soluble ICAM-1 and CXCL13 in the therapeutic response to TNF inhibitor in rheumatoid arthritis patients who are refractory to csDMARDs"],"prefix":"10.1007","volume":"39","author":[{"given":"Juan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,23]]},"reference":[{"key":"5043_CR1","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1136\/ard.2008.099861","volume":"68","author":"W Katchamart","year":"2009","unstructured":"Katchamart W, Trudeau J, Phumethum V, Bombardier C (2009) Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 68:1105\u20131112","journal-title":"Ann Rheum Dis"},{"key":"5043_CR2","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJMct055183","volume":"355","author":"DL Scott","year":"2006","unstructured":"Scott DL, Kingsley GH (2006) Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 355:704\u2013712","journal-title":"N Engl J Med"},{"key":"5043_CR3","first-page":"497","volume":"33","author":"Y Braun-Moscovici","year":"2006","unstructured":"Braun-Moscovici Y, Markovits D, Zinder O, Schapira D, Rozin A, Ehrenburg M, Dain L, Hoffer E, Nahir AM, Balbir-Gurman A (2006) Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. J Rheumatol 33:497\u2013500","journal-title":"J Rheumatol"},{"key":"5043_CR4","first-page":"83","volume":"19","author":"LM Canet","year":"2019","unstructured":"Canet LM, S\u00e1nchez-Maldonado JM, C\u00e1liz R, Rodr\u00edguez-Ramos A, Lupia\u00f1ez CB, Canh\u00e3o H, Mart\u00ednez-Bueno M, Escudero A, Segura-Catena J, Sorensen SB, Hetland ML, Soto-Pino MJ, Ferrer MA, Garc\u00eda A, Glintborg B, Filipescu I, P\u00e9rez-Pampin E, Gonz\u00e1lez-Utrilla A, Nevot M\u00c1L, Conesa-Zamora P, Broeder AD, de Vita S, Jacobsen SEH, Collantes-Estevez E, Quartuccio L, Canzian F, Fonseca JE, Coenen MJH, Andersen V, Sainz J (2019) Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients. Pharm J 19:83\u201396","journal-title":"Pharm J"},{"key":"5043_CR5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/00000441-200204000-00002","volume":"323","author":"JK Jenkins","year":"2002","unstructured":"Jenkins JK, Hardy KJ, McMurray RW (2002) The pathogenesis of rheumatoid arthritis: a guide to therapy. Am J Med Sci 323:171\u2013180","journal-title":"Am J Med Sci"},{"key":"5043_CR6","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.3899\/jrheum.081074","volume":"36","author":"T Odai","year":"2009","unstructured":"Odai T, Matsunawa M, Takahashi R, Wakabayashi K, Isozaki T, Yajima N, Miwa Y, Kasama T (2009) Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis. J Rheumatol 36:1158\u20131165","journal-title":"J Rheumatol"},{"key":"5043_CR7","doi-asserted-by":"publisher","first-page":"R90","DOI":"10.1186\/ar4555","volume":"16","author":"G Dennis Jr","year":"2014","unstructured":"Dennis G Jr, Holweg CT, Kummerfeld SK, Choy DF, Setiadi AF, Hackney JA et al (2014) Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res Ther 16:R90","journal-title":"Arthritis Res Ther"},{"key":"5043_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13075-016-0995-0","volume":"18","author":"BK Han","year":"2016","unstructured":"Han BK, Kuzin I, Gaughan JP, Olsen NJ, Bottaro A (2016) Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study. Arthritis Res Ther 18:93","journal-title":"Arthritis Res Ther"},{"key":"5043_CR9","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1186\/s13075-014-0434-z","volume":"16","author":"SR Greisen","year":"2014","unstructured":"Greisen SR, Schelde KK, Rasmussen TK, Kragstrup TW, Stengaard-Pedersen K, Hetland ML et al (2014) CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic \u2018window of opportunity\u2019. Arthritis Res Ther 16:434","journal-title":"Arthritis Res Ther"},{"key":"5043_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12865-015-0068-1","volume":"16","author":"E Klimatcheva","year":"2015","unstructured":"Klimatcheva E, Pandina T, Reilly C, Torno S, Bussler H, Scrivens M et al (2015) CXCL13 antibody for the treatment of autoimmune disorders. BMC Immunol 16:6","journal-title":"BMC Immunol"},{"key":"5043_CR11","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.4049\/jimmunol.167.4.1920","volume":"167","author":"L Mandik-Nayak","year":"2001","unstructured":"Mandik-Nayak L, Huang G, Sheehan KC, Erikson J, Chaplin DD (2001) Signaling through TNF receptor p55 in TNF-alpha-deficient mice alters the CXCL13\/CCL19\/CCL21 ratio in the spleen and induces maturation and migration of anergic B cells into the B cell follicle. J Immunol 167:1920\u20131928","journal-title":"J Immunol"},{"key":"5043_CR12","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1002\/art.38173","volume":"65","author":"S Kobayashi","year":"2013","unstructured":"Kobayashi S, Murata K, Shibuya H, Morita M, Ishikawa M, Furu M, Ito H, Ito J, Matsuda S, Watanabe T, Yoshitomi H (2013) A distinct human CD4+ T cell subset that secretes CXCL13 in rheumatoid synovium. Arthritis Rheum 65:3063\u20133072","journal-title":"Arthritis Rheum"},{"key":"5043_CR13","doi-asserted-by":"publisher","first-page":"R103","DOI":"10.1186\/ar4552","volume":"16","author":"JD Jones","year":"2014","unstructured":"Jones JD, Hamilton BJ, Challener GJ, de Brum-Fernandes AJ, Cossette P, Liang P et al (2014) Serum C-X-C motif chemokine 13 is elevated in early and established rheumatoid arthritis and correlates with rheumatoid factor levels. Arthritis Res Ther 16:R103","journal-title":"Arthritis Res Ther"},{"key":"5043_CR14","doi-asserted-by":"publisher","first-page":"R34","DOI":"10.1186\/ar3742","volume":"14","author":"S Bugatti","year":"2012","unstructured":"Bugatti S, Manzo A, Benaglio F, Klersy C, Vitolo B, Todoerti M et al (2012) Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs. Arthritis Res Ther 14:R34","journal-title":"Arthritis Res Ther"},{"key":"5043_CR15","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB Mcinnes","year":"2011","unstructured":"Mcinnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205\u20132219","journal-title":"N Engl J Med"},{"key":"5043_CR16","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1530\/REP-09-0196","volume":"138","author":"M Pino","year":"2009","unstructured":"Pino M, Galleguillos C, Torres M, Sovino H, Fuentes A, Boric MA, Johnson MC (2009) Association between MMP1 and MMP9 activities and ICAM1 cleavage induced by tumor necrosis factor in stromal cell cultures from eutopic endometria of women with endometriosis. Reproduction 138:837\u2013847","journal-title":"Reproduction"},{"key":"5043_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.imlet.2012.04.013","volume":"145","author":"E Corsiero","year":"2012","unstructured":"Corsiero E, Bombardieri M, Manzo A, Bugatti S, Uguccioni M, Pitzalis C (2012) Role of lymphoid chemokines in the development of functional ectopic lymphoid structures in rheumatic autoimmune diseases. Immunol Lett 145:62\u201367","journal-title":"Immunol Lett"},{"key":"5043_CR18","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1002\/art.23667","volume":"58","author":"I Rioja","year":"2008","unstructured":"Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, Wilson AG, Binks MH, Dickson MC (2008) Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum 58:2257\u20132267","journal-title":"Arthritis Rheum"},{"key":"5043_CR19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/03009740310004054","volume":"33","author":"M Ugur","year":"2004","unstructured":"Ugur M, Yildirim K, Kiziltunc A, Erdal A, Karatay S, Senel K (2004) Correlation between soluble intercellular adhesion molecule 1 level and extracellular superoxide dismutase activity in rheumatoid arthritis: a possible association with disease activity. Scand J Rheumatol 33:239\u2013243","journal-title":"Scand J Rheumatol"},{"key":"5043_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13075-017-1224-1","volume":"19","author":"JM Pandya","year":"2017","unstructured":"Pandya JM, Lundell AC, Andersson K, Nordstr\u00f6m I, Theander E, Rudin A (2017) Blood chemokine profile in untreated early rheumatoid arthritis: CXCL10 as a disease activity marker. Arthritis Res Ther 19:20","journal-title":"Arthritis Res Ther"},{"key":"5043_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/art.1780360412","volume":"36","author":"JC Mason","year":"1993","unstructured":"Mason JC, Kapahi P, Haskard DO (1993) Detection of increased levels of circulating intercellular adhesion molecule 1 in some patients with rheumatoid arthritis but not in patients with systemic lupus erythematosus. Lack of correlation with levels of circulating vascular cell adhesion molecule 1. Arthritis Rheum 36:519\u2013527","journal-title":"Arthritis Rheum"},{"key":"5043_CR22","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3109\/03009749509095183","volume":"24","author":"T Jonsson","year":"1995","unstructured":"Jonsson T, Arinbjarnarson S, Thorsteinsson J, Steinsson K, Geirsson AJ, J\u00f3nsson H et al (1995) Raised IgA rheumatoid factor (RF) but not IgM RF or IgG RF is associated with extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 24:372\u2013375","journal-title":"Scand J Rheumatol"},{"key":"5043_CR23","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1136\/ard.2004.033571","volume":"64","author":"J Ronnelid","year":"2005","unstructured":"Ronnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L et al (2005) Longitudinal analysis of citrullinated protein\/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 64:1744\u20131749","journal-title":"Ann Rheum Dis"},{"key":"5043_CR24","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/art.30273","volume":"63","author":"CM Meeuwisse","year":"2011","unstructured":"Meeuwisse CM, Van Der Linden MP, Rullmann TA, Allaart CF, Nelissen R, Huizinga TW et al (2011) Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint. Arthritis Rheum 63:1265\u20131273","journal-title":"Arthritis Rheum"},{"key":"5043_CR25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/ard.61.4.311","volume":"61","author":"AA Den Broeder","year":"2002","unstructured":"Den Broeder AA, Joosten A, Saxne T, Heineg\u00e5rd D, Fenner H, Miltenburg AM et al (2002) Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 61:311\u2013318","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05043-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-020-05043-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05043-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:40:17Z","timestamp":1616460017000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-020-05043-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,23]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["5043"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05043-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,23]]},"assertion":[{"value":"26 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was granted for this study, and consent was obtained from all the subjects. All patients provided their informed consent, and the study was conducted according to the principles of the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}